UK Markets closed
NIKKEI 225
26,547.05 +119.40 (+0.45%) HANG SENG
19,950.21 +51.44 (+0.26%) CRUDE OIL
112.77 +2.28 (+2.06%) GOLD FUTURES
1,811.20 +3.00 (+0.17%) DOW
32,184.75 -11.91 (-0.04%) BTC-GBP
24,023.94 -617.83 (-2.51%)
Akebia Therapeutics, Inc. (AKBA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 12:37PM EDT. Market open.
| Previous close | 0.4492 |
| Open | 0.3550 |
| Bid | 0.3639 x 900 |
| Ask | 0.3653 x 2900 |
| Day's range | 0.3502 - 0.3864 |
| 52-week range | 0.3450 - 4.3300 |
| Volume | |
| Avg. volume | 10,952,090 |
| Market cap | 64.053M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8870 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.17 |
- Zacks
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2022 Yahoo. All rights reserved.
